The Utility of Ischemia Modified Albumin (IMA) in Sepsis

Completed

Conditions studied: Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome, Sepsis Syndrome

In brief

The purpose of this study is to determine if levels of ischemia modified albumin (IMA) in blood are elevated in patients with suspected infection and are predictive of severity of illness in patients with sepsis. In order to compare subjects with infection to those without infection who are representative of the ED population at each site, a group of non-infected control patients will be enrolled. Each hospital will enroll subjects with age (by decade) and sex matched controls to reflect the population of subjects suspected of infection.

Key facts

Study ID

NCT00448968

Run by

Inverness Medical Innovations

People needed

150

Starts

2007-03-01

Expected to finish

2007-09-01

Last updated by the study team

2007-09-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Cleveland Clinc — Cleveland, Ohio, United States
• University of Pennsylvania School of Medicine — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.